Compare DexCom, Inc. (DXCM) vs S&P Global Inc (SPGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs S&P Global Inc — how do they compare? DexCom, Inc. trades at $77.81 (market cap $28.06B), while S&P Global Inc trades at $448.13 (market cap $131.57B). The key difference: S&P Global Inc is far larger — about 4.7× DexCom, Inc.'s market cap, and S&P Global Inc pays a 0.87% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | SPGI | |
|---|---|---|
Market Cap | $28.06B | $131.57B |
Sector | Health | Financials |
52-Week High | $89.53 | $534.79 |
52-Week Low | $54.84 | $370.42 |
Enterprise Value | $27.03B | $143.53B |
Dividend Yield | — | 0.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
S&P Global (SPGI) trades at $438.87, showing modest daily gains amid a bullish technical signal from moving averages. The company demonstrates strong fundamentals with revenue growth to $15.34B in 2025 and robust net income margins of 30.36%, supported by consistent earnings beats. Recent developments include the successful spin-off of Mobility Global and strategic focus on AI-driven analytics through its Market Intelligence segment, positioning the company for continued margin expansion.
The outlook remains positive with 85.7% analyst buy ratings and a $532.38 consensus price target representing 21% upside. Key opportunities include structural growth in API usage linked to AI adoption and resilient recurring revenue streams. Primary risks involve competitive threats to core ratings business, integration challenges from recent restructuring, and sensitivity to capital market activity affecting debt issuance volumes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About S&P Global Inc
S&P Global provides data and benchmarks to capital and commodity market participants. In 2021 and excluding IHS Markit, S&P Ratings was over 45% of the firm's revenue and over 55% of the firm's operating income. S&P Ratings is the largest credit rating agency in the world. The firm's other segments include Market Intelligence, Indices, and Platts. Market Intelligence provides desktop tools and other data solutions to investment banks, corporations, and other entities. Indices provides benchmarks for financial markets and is monetized through subscriptions, asset-based fees, and transaction-based royalties. Platts provides benchmarks to commodity markets, principally petroleum.
Read more on SPGI →
